Results 11 to 20 of about 2,969,292 (313)

Correction to: Design considerations of an IL13Rα2 antibody–drug conjugate for difuse intrinsic pontine glioma

Acta Neuropathologica Communications, 2021
An amendment to this paper has been published and can be accessed via the original article.
Xiaolei Lian, Dina Kats, Samuel Rasmussen, Leah R. Martin, Anju Karki, Charles Keller, Noah E. Berlow   +6 more
doaj   +1 more source

Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma

Acta Neuropathologica Communications, 2021
Diffuse intrinsic pontine glioma (DIPG), a rare pediatric brain tumor, afflicts approximately 350 new patients each year in the United States. DIPG is noted for its lethality, as fewer than 1% of patients survive to five years.
Xiaolei Lian, Dina Kats, Samuel Rasmussen, Leah R. Martin, Anju Karki, Charles Keller, Noah E. Berlow   +6 more
doaj   +1 more source

Targeted cancer therapies [PDF]

Chinese Journal of Cancer, 2011
With unprecedented understanding of molecular events underlying human cancer in this genomic era, a large number of drugs specifically targeting hypothesized oncogenic drivers to which tumors are potentially addicted to have been developed and continue to be developed.
Yan, Li, Rosen, Neal, Arteaga, Carlos
openaire   +2 more sources

Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing

Molecular Cancer, 2023
Background Chimeric Antigen Receptor (CAR) T cells are now standard of care (SOC) for some patients with B cell and plasma cell malignancies and could disrupt the therapeutic landscape of solid tumors.
Hyatt Balke-Want, Vimal Keerthi, Nikolaos Gkitsas, Andrew G. Mancini, Gavin L. Kurgan, Carley Fowler, Peng Xu, Xikun Liu, Kyle Asano, Sunny Patel, Christopher J. Fisher, Annie K. Brown, Ramya H. Tunuguntla, Shabnum Patel, Elena Sotillo, Crystal L. Mackall, Steven A. Feldman   +16 more
doaj   +1 more source

DMXL2 drives epithelial to mesenchymal transition in hormonal therapy resistant breast cancer through Notch hyper-activation [PDF]

, 2015
The acquisition of endocrine therapy resistance in estrogen receptor a (ERa) breast cancer patients represents a major clinical problem. Notch signalling has been extensively linked to breast cancer especially in patients who fail to respond to endocrine
Aifantis, Apatira, Apweiler, Brennan, Carroll, Chazotte, Chen, Coombes, Darbre, Eikesdal, Forgac, Goloubeva, Gul, Hill, Ho, Joffe, Johnston, Jones, Jones, Jones, Kane, Kang, Kocak, Lake, Le Borgne, Lendahl, Liu, Lupien, Mader, Mao, Martinez, McPherson, Medici, Meyer, Miele, Miele, Miele, Miyamoto, Nguyen, Nicolson, Roegiers, Sarkar, Schiff, Schilling, Schupbach, Sutherland, Taylor, Urbe, Vaccari, Venkanteshan, Wang, Webster, Wieczorek, Wong, Zahler   +54 more
core   +6 more sources

Preclinical therapeutics ex ovo quail eggs as a biomimetic automation-ready xenograft platform

Scientific Reports, 2021
Preclinical cancer research ranges from in vitro studies that are inexpensive and not necessarily reflective of the tumor microenvironment to mouse studies that are better models but prohibitively expensive at scale. Chorioallantoic membrane (CAM) assays
Samuel V. Rasmussen, Noah E. Berlow, Lisa Hudson Price, Atiya Mansoor, Stefano Cairo, Sandra Rugonyi, Charles Keller   +6 more
doaj   +1 more source

Application of Ultrasound Combined with DSA-guided Single-incision Technique via Axillary Vein Access in Implantation of Totally Implantable Venous Access Port

Zhongliu Fangzhi Yanjiu, 2021
Objective To evaluate the technical feasibility and safety of a single-incision technique via axillary vein (AV) for placement of totally implantable venous access port (TIVAP) guided by ultrasound combined with DSA in clinical application.
LIU Weifu, ZHANG Kongzhi, YU Wenchang, CHEN Shiguang, WAN Xiaolong   +4 more
doaj   +1 more source

Individualizing cancer therapy [PDF]

Leukemia & Lymphoma, 2010
In this issue of Leukemia and Lymphoma, Ngo and colleagues describe the predictive value of cyclin D1 expression as a predictor of bortezomib response in multiple myeloma. The ability to predict treatment response based on genetic expression would be of value, if it could be confirmed in a larger study.
Morie A, Gertz, Tamar, Tadmor
openaire   +2 more sources

Feasibility of linac-based fractionated stereotactic radiotherapy and stereotactic radiosurgery for patients with up to ten brain metastases

Radiation Oncology, 2022
Background Linac-based fractionated stereotactic radiotherapy (fSRT) and stereotactic radiosurgery (SRS) are increasingly being used to manage patients with multiple metastases.
Masanori Hirata, Kazuaki Yasui, Naofumi Oota, Hirofumi Ogawa, Tsuyoshi Onoe, Sayo Maki, Yusuke Ito, Kenji Hayashi, Hirofumi Asakura, Shigeyuki Murayama, Koichi Mitsuya, Shoichi Deguchi, Katsumasa Nakamura, Nakamasa Hayashi, Tetsuo Nishimura, Hideyuki Harada   +15 more
doaj   +1 more source

Fluorescent imaging for cancer therapy and cancer gene therapy [PDF]

Molecular Therapy - Oncolytics, 2021
The translation of laboratory science into effective clinical cancer therapy is gaining momentum more rapidly than any other time in history. Understanding cancer cell-surface receptors, cancer cell growth, and cancer metabolic pathways has led to many promising molecular-targeted therapies and cancer gene therapies.
Yanghee Woo, Shyambabu Chaurasiya, Michael O’Leary, Ernest Han, Yuman Fong   +4 more
openaire   +3 more sources